<p>在最新的季度中，7 位分析师对贝克顿·迪金森（NYSE: BDX）提供了评级，展现出看涨和看跌的不同观点。</p>
<p>下表提供了他们最近评级的快照，展示了过去 30 天情绪的演变，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>在对 12 个月价格目标的评估中，分析师为贝克顿·迪金森提供了见解，呈现出 205.57 美元的平均目标，最高预估为 215.00 美元，最低预估为 190.00 美元。当前平均目标较之前的 200.00 美元上升了 2.78%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626872_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626872_0.png"/></p>
<h2>分析师评级调查：详尽研究</h2>
<p>通过最近的分析师行动，分析了金融专家对贝克顿·迪金森的看法。以下摘要呈现了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>中性</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>上调</td>
<td>中性</td>
<td>$207.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上调</td>
<td>行业表现</td>
<td>$210.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>$210.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下调</td>
<td>行业表现</td>
<td>$202.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>下调</td>
<td>中性</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对贝克顿·迪金森近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师提供全面分析，给出定性评估，范围从 “跑赢大盘” 到 “跑输大盘”。这些评级反映了对贝克顿·迪金森相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供对贝克顿·迪金森股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>为了全面了解贝克顿·迪金森的市场表现，请探索这些分析师评估以及重要的财务指标。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解贝克顿·迪金森的分析师评级。</p>
<h2>深入了解贝克顿·迪金森的背景</h2>
<p>贝克顿·迪金森是全球最大的医疗外科产品制造和分销商，产品包括针头、注射器和锐器处置单元。该公司还制造预填充设备、诊断仪器和试剂，以及流式细胞仪和细胞成像系统。BD Medical 几乎占总业务的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）占其余部分。国际收入占公司业务的 43%。</p>
<h3>分析贝克顿·迪金森的财务表现</h3>
<p><strong>市值分析：</strong> 公司的市值高于行业平均水平，表明其相对于同行规模较大。这可能暗示着更高的投资者信心和市场认可度。</p>
<p><strong>收入增长：</strong> 贝克顿·迪金森在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，公司实现了约 <strong>8.35%</strong> 的收入增长率。这表明公司的顶线收益有了显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> 公司的净利润率表现突出，超过行业平均水平。凭借 <strong>8.37%</strong> 的净利润率，公司展现出强劲的盈利能力和有效的成本控制。</p>
<p><strong>股本回报率（ROE）：</strong> 贝克顿·迪金森的 ROE 低于行业平均水平，表明在最大化股本回报方面面临挑战。ROE 为 <strong>1.94%</strong>，公司可能在实现最佳财务表现方面面临困难。</p>
<p><strong>资产回报率（ROA）：</strong> 贝克顿·迪金森的 ROA 低于行业平均水平，表明在最大化资产回报方面面临挑战。ROA 为 <strong>0.89%</strong>，公司可能在实现最佳财务表现方面面临困难。</p>
<p><strong>债务管理：</strong> 贝克顿·迪金森的债务与股本比率为 <strong>0.76</strong>，低于行业平均水平，反映出对债务融资的依赖较低，财务策略更为保守。</p>
<h2>分析师评级的基础知识</h2>
<p>在银行和金融系统领域，分析师专注于特定股票或定义的行业进行报告。他们的工作包括参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 “分析师评级”。分析师通常每季度评估和评级每只股票一次。</p>
<p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以便为他们的评级提供额外的指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供他们的意见。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

美国医药设备 ETF - iShares

碧迪医疗

标普健康医疗设备 ETF - SPDR

<p>在最新的季度中，7 位分析师对碧迪医疗（NYSE:BDX）给出了混合评级，12 个月的平均目标价为 205.57 美元，较之前的目标价上涨了 2.78%。分析师根据市场情况调整了他们的评级，其中皮博格·桑德勒（Piper Sandler）和斯蒂费尔（Stifel）等公司的变化尤为显著。作为领先的医疗产品制造商，碧迪医疗显示出 8.35% 的强劲收入增长，但在股本回报率和资产回报率方面面临挑战。该公司的债务与股本比率低于行业平均水平，表明其采取了保守的财务策略</p>

<p>In the latest quarter, 7 analysts provided ratings for Becton Dickinson (NYSE: BDX), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，7 位分析师对贝克顿·迪金森（NYSE: BDX）提供了评级，展现出看涨和看跌的不同观点。</p>
</div><p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快照，展示了过去 30 天情绪的演变，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>In the assessment of 12-month price targets, analysts unveil insights for Becton Dickinson, presenting an average target of $205.57, a high estimate of $215.00, and a low estimate of $190.00. Witnessing a positive shift, the current average has risen by 2.78% from the previous average price target of $200.00.</p>
<div class="lb-trans"><p>在对 12 个月价格目标的评估中，分析师为贝克顿·迪金森提供了见解，呈现出 205.57 美元的平均目标，最高预估为 215.00 美元，最低预估为 190.00 美元。当前平均目标较之前的 200.00 美元上升了 2.78%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626872_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769626872_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析师评级调查：详尽研究</h2>
</div><p>The perception of Becton Dickinson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过最近的分析师行动，分析了金融专家对贝克顿·迪金森的看法。以下摘要呈现了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$207.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$210.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$202.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>中性</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>上调</td>
<td>中性</td>
<td>$207.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上调</td>
<td>行业表现</td>
<td>$210.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>$210.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下调</td>
<td>行业表现</td>
<td>$202.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>下调</td>
<td>中性</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Becton Dickinson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Becton Dickinson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对贝克顿·迪金森近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师提供全面分析，给出定性评估，范围从 “跑赢大盘” 到 “跑输大盘”。这些评级反映了对贝克顿·迪金森相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供对贝克顿·迪金森股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>To gain a panoramic view of Becton Dickinson's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了全面了解贝克顿·迪金森的市场表现，请探索这些分析师评估以及重要的财务指标。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on Becton Dickinson analyst ratings.</p>
<div class="lb-trans"><p>随时了解贝克顿·迪金森的分析师评级。</p>
</div><h2>Delving into Becton Dickinson's Background</h2>
<div class="lb-trans"><h2>深入了解贝克顿·迪金森的背景</h2>
</div><p>Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.</p>
<div class="lb-trans"><p>贝克顿·迪金森是全球最大的医疗外科产品制造和分销商，产品包括针头、注射器和锐器处置单元。该公司还制造预填充设备、诊断仪器和试剂，以及流式细胞仪和细胞成像系统。BD Medical 几乎占总业务的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）占其余部分。国际收入占公司业务的 43%。</p>
</div><h3>Breaking Down Becton Dickinson's Financial Performance</h3>
<div class="lb-trans"><h3>分析贝克顿·迪金森的财务表现</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值高于行业平均水平，表明其相对于同行规模较大。这可能暗示着更高的投资者信心和市场认可度。</p>
</div><p><strong>Revenue Growth:</strong> Becton Dickinson's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>8.35%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 贝克顿·迪金森在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，公司实现了约 <strong>8.35%</strong> 的收入增长率。这表明公司的顶线收益有了显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.37%,</strong> the company showcases strong profitability and effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 公司的净利润率表现突出，超过行业平均水平。凭借 <strong>8.37%</strong> 的净利润率，公司展现出强劲的盈利能力和有效的成本控制。</p>
</div><p><strong>Return on Equity (ROE):</strong> Becton Dickinson's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.94%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 贝克顿·迪金森的 ROE 低于行业平均水平，表明在最大化股本回报方面面临挑战。ROE 为 <strong>1.94%</strong>，公司可能在实现最佳财务表现方面面临困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> Becton Dickinson's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.89%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 贝克顿·迪金森的 ROA 低于行业平均水平，表明在最大化资产回报方面面临挑战。ROA 为 <strong>0.89%</strong>，公司可能在实现最佳财务表现方面面临困难。</p>
</div><p><strong>Debt Management:</strong> Becton Dickinson's debt-to-equity ratio is below the industry average at <strong>0.76</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 贝克顿·迪金森的债务与股本比率为 <strong>0.76</strong>，低于行业平均水平，反映出对债务融资的依赖较低，财务策略更为保守。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析师评级的基础知识</h2>
</div><p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>在银行和金融系统领域，分析师专注于特定股票或定义的行业进行报告。他们的工作包括参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 “分析师评级”。分析师通常每季度评估和评级每只股票一次。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以便为他们的评级提供额外的指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供他们的意见。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

分析师的判决：7 位专家眼中的碧迪医疗